Lexitas Pharma Services, a clinical research organization focused on ophthalmology, has acquired Erie Retina Research. The deal expands Lexitas's capabilities in retinal disease research and clinical trials. QHP Capital backed the transaction as part of a broader strategy to consolidate specialized contract research organizations in the pharmaceutical services sector.

Lexitas operates as a full-service ophthalmology CRO, providing clinical development services for eye-related therapies and devices. The addition of Erie Retina Research strengthens their expertise in retinal disorders, a therapeutic area with growing demand as new gene and drug therapies emerge. This vertical integration allows Lexitas to offer more comprehensive services to pharmaceutical clients developing treatments for age-related macular degeneration, diabetic retinopathy, and inherited retinal diseases.

The acquisition reflects continued private equity interest in specialized CROs that serve high-value therapeutic niches. Ophthalmology clinical trials require unique expertise and specialized equipment, creating barriers to entry that benefit focused players. Erie Retina Research brings additional clinical sites and investigator relationships that enhance Lexitas's ability to conduct complex retinal studies.